Program
ITU512
A development code.
In Novartis's pipeline, HbF inducing agent
. Its studies are mostly in Anemia, Sickle Cell, led by Novartis.
Furthest: phase 2, since Jul 16, 20241 company-led study, 1 open or runningNext primary completion: May 1, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 11 open or running | phase 2since Jul 16, 2024 | Jul 16, 2024 | May 1, 2028phase 2 · NCT06546670 |
- Named in Novartis’s own pipeline as
ITU512
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 16, 2024First study: phase 2 study in Anemia, Sickle CellFirst studyNCT06546670 · 161 planned · United States, Brazil, Turkey (Türkiye)
Ahead
- May 1, 2028Primary completion: phase 2 study in Anemia, Sickle CellNCT06546670
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“HbF inducing agent”the company's pipeline, read by Claude · source
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06546670Anemia, Sickle Cell · United States, Brazil, Turkey (Türkiye) | 2 | Recruiting | May 1, 2028 | 161 |
How it is read
Names in the registry
- “ITU512”, 1 entry
Codes read as this program: ITU512.
Conditions, from the studies’ own filings
- Anemia, Sickle Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.